Intocell Overview

Founded 2015
Status Private
Latest Deal Type Series B
Investors 3

Intocell General Information


Developer of biotechnology platform designed to develop antibody-drug conjugate. The company's offerings include development and commercialization of novel ADC through comprising scaffold moiety, ligands, toxins, linkers and conjugation methods, enabling doctors to treat cancer through the development of new drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Primary Office
  • 101, Sinildong-ro
  • Daejeon, Daedeok-gu 34302
  • South Korea
+82 000-000-0000

Intocell Timeline

Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Intocell Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series B) Completed Generating Revenue
5. Grant 30-Nov-2016 Completed Generating Revenue
4. Early Stage VC 27-Sep-2016 Completed Generating Revenue
3. Early Stage VC (Series A) 30-Jan-2016 Completed Generating Revenue
2. Grant 31-Dec-2015 Completed Startup
1. Early Stage VC 29-Apr-2015 Completed Startup

Intocell Executive Team (1)

Name Title Board Seat Contact Info
Tae Park Ph.D Chief Executive Officer

Intocell Investors (3)

To view Intocell‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Atinum Investment Venture Capital Minority 000 0000 000000 0
Stonebridge Capital Venture Capital Minority 000 0000 000000 0
Partners Investment Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial